alexa Safety and Potency Test for PV and ERA Based Cell Cultu
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Safety and Potency Test for PV and ERA Based Cell Culture Anti-Rabies Vaccines Produced in Ethiopia

Abebe Mengesha1*, Birhanu Hurisa1, Bethlehem Newayesilasie1, Mekoro Beyene1, Denis Bankovisky2, Arthem Metlin3 and Kelbessa Urga1
1Ethiopian Health and Nutrition Research Institute, Ethiopia
2Pokrov Plant of Biologics, Russian Federation, Russia
3Federal Center for Animal Health, Russian Federation, Russia
Corresponding Author : Abebe Mengesha
Ethiopian Health and Nutrition Research Institute, Ethiopia
Tel: 251 11 2133499
E-mail: [email protected] or [email protected]
Received April 14, 2014; Accepted June 14, 2014; Published June 24, 2014
Citation: Mengesha A, Hurisa B, Newayesilasie B, Beyene M, Bankovisky D, et al. (2014) Safety and Potency Test for PV and ERA Based Cell Culture Anti-Rabies Vaccines Produced in Ethiopia. J Vaccines Vaccin 5:237. doi:10.4172/2157-7560.1000237
Copyright: © 2014 Mengesha A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 

Abstract

This research was aimed to evaluate safety and potency of PV and ERA based cell culture anti-rabies vaccines. Two rabies vaccinal strains (PV and ERA) used to produce virus suspension propagated on Vero and BHK-21 cell lines. Potency and safety of the vaccine studied after inactivation with formalin. Safety test performed to access residual virulent left during inactivation or to detect any bacteriological contaminant present in the crude vaccine, and no residual virus or bacterial contaminant was detected. Potency test determines the degree of protection conferred by the vaccine in immunized mice challenged with challenge virus standard. This test was performed using National Institutes of Health (NIH) potency test. Mice were immunized on day 0 and 7 with five different concentrations of test vaccine and four different concentrations of control vaccine, 16 mice in each dilution. The control vaccine used was VeroRab vaccine which was produced by Sanofi Pasteur. Standard CVS strain obtained from CDC Atlanta was used for challenging. Mice were challenged on day 14th with challenge virus strain (CVS-11) of 25 MLD50/0.03ml intra-cerebrally. The mice were observed for 14 days and death recorded for each dilution separately. Potency result calculated using NIH test and 8.32 IU/ml for ERA and 3.56 IU/ml for PV results were obtained. Based on WHO recommendation, these vaccines have high potency and upon dilution can be used for animal immunization.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords